A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants
Tekijät: Guo, Ling; Kenmoe, Sebastien; Miyake, Fuyu; Chung, Alexandria; Zhang, Han; Bandeira, Teresa; Caballero, Mauricio T.; Casalegno, Jean-Sebastien; Fasce, Rodrigo; Giorgi, Chakhunashvili; Heikkinen, Terho; Huang, Q. Sue; Katama, Esther Nyadzua; Keck, James W.; Liu, Enmei; Markic, Josko; Moore, Hannah C.; Moyes, Jocelyn; Rath, Barbara A.; Romero, Candice; Wang, Qianli; Werner, Marta; Yung, Chee Fu, Respiratory Virus Global Epidemiology Network; Nair, Harish; Li, You; PROMISE investigators
Kustantaja: NATURE PORTFOLIO
Kustannuspaikka: BERLIN
Julkaisuvuosi: 2025
Journal: Nature Communications
Tietokannassa oleva lehden nimi: NATURE COMMUNICATIONS
Lehden akronyymi: NAT COMMUN
Artikkelin numero: 6109
Vuosikerta: 16
Numero: 1
Sivujen määrä: 13
eISSN: 2041-1723
DOI: https://doi.org/10.1038/s41467-025-61400-1
Verkko-osoite: https://www.nature.com/articles/s41467-025-61400-1
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/499249780
Understanding the distribution of respiratory syncytial virus (RSV) disease burden by more granular age bands in infants is necessary for optimising infant RSV immunisation strategies. Using a Bayesian model, we synthesised published data from a systematic literature review and unpublished data shared by international collaborators for estimating the distribution of infant RSV hospitalisations by month of age. Based on local RSV seasonality data, we further developed and validated a web-based prediction tool for estimating infant RSV hospitalisation distribution by birth month. Although RSV hospitalisation burden mostly peaked at the second month of life and was concentrated in infants under six months globally, substantial variations were noted in the age distribution of RSV hospitalisation among infants born in different months. Passive immunisation strategies should ideally be tailored to the local RSV disease burden distribution by age and birth month to maximise their per-dose effectiveness before a universal immunisation can be achieved.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
The study is supported by the PROMISE project, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (under grant agreement number 101034339), and WHO through a grant from the Bill & Melinda Gates Foundation (number INV-005318). The Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.
The study was funded through CDC Interagency Agreement: 18FED1812054IPD. The study protocol (NAMRU6 2016.0007) was approved by the U.S. Naval Medical Research Unit SOUTH (NAMRU-SOUTH) Institutional Review Board in compliance with all applicable federal regulations governing the protection of human subjects. Y.L. acknowledged grant support from the National Natural Science Foundation of China (No. 82473692).
